FORM PTO-1449

MAY 1 2 2003

U.S. Dept. of Commerce Patent and Trademark Office

Atty Docket No. P3121R1

Serial No. 09/964,994

Applicant

Audrey Goddard et al.

Filing Date 26 Sep 2001

Group 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner	-	T		U.S. PATENT DUCUMENTS			
nitials		Document Number	Date	Name	Class	Subclass	Filing Date
	1	4,179,337	18.12.79	Davis et al.	 	 	Filing Date
	2	4,275,149	23.06.81	Litman et al.		REC	
`	3	4,301,144	17.11.81	Iwashita et al.			EIVED
	4	4,496,689	29.01.85	Mitra, G.		MAY	
	5	4,640,835		Shimizu et al.			1 5 2003
	6	4,657,760		Kung et al.	TE	CH CENT	R 1600/2900
	7	4,670,417	02.06.87	Iwasaki et al.		3.1 OLJV/	<i>'R 1600/2</i> 900 -
	8	4,676,980		Segal et al.			
	9	4,736,866	3	Leder et al.			•
,	10	4,791,192	13.12.88	Nakagawa et al.			
	11	4,816,567			(1)	-9	
	12	4,870,009		Evans et al.	CATE	50	
	13	5,206,344	27.04.93	Katre et al.			
	14	5,225,212	06.07.94	Martin et al.		1	
- 1	15	5,364,934	15.11.94	Drayna et al.			
	16	5,536,637		Jacobs, K.	. 1	1	
	17	5,545,806	13.08.96 I	Comberg et al.		1	
	18	5,545,807		Surani et al.			
	19	5,569,825	29.10.96 I	onberg et al.	1		
17	20	5 625,126	29.04.97 L	onberg et al.			
	24	5,633,425	27.05.97 L	onberg et al.	1	1	
1	22 5	5,654,010		ohnson et al.			
	23 5	5,661,016		onberg et al.			

FOREIGN PATENT DOCUMENTS

xaminer itials		D		TOTILIGIT PATENT DOCUMENTS				
		Document Number	Date	Country	Class	Subclass	Transla	
COZ	24	3089	25.07.79	EP (ENGLISH CLAIMS)	01000	Subclass	Yes	No
1	25	404,097	27.12.90	EP (ENGLISH ABSTRACT ATTACHED)				
	26	WO 90/13641	15.11.90	PCT			 	
1	27	WO 91/00360	10.01.91	PCT		•		
1 1	28	WO 92/20373	26.11.92	PCT				
	29	WO 93/08829	13.05.93	PCT		X		
	30	WO 93/11161	10.06.93	PCT				
	31	WO 96/07399	14.03.96	PCT		1		
	32	WO 96/27011	06.09.96	PCT		[
	33	WO 96/40072	19.12.96	PCT			1	
aminer	L				-			
	_@	. I work w			Considered 6/3	30/13		
kaminer	: Initi	al if reference consider	ed whether or -			700		

E. Memmeres *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		<u></u>	/O ·				ļ		Sheet 3 of
FORM	PTO-	1449	MAY 1	2 2000		U.S. Dept	. of Commerce	Atty Docket No.	Serial No.
				E		Patent and T	Fradamada Offi	P3121R1	09/954_994
LICT	SE DI	201 00U	The state of the s	APPLICAL		raterit and 1	Trademark Office	Applicant	
rio! (JF DR	SCLUSU	HES CHEE	BYAPPLICAL	NT			Audrey Goddard	した
(Us	se sev	eral shee	ts if necess	arv)					
								Filing Date 26 Sep 2001	Group"47 1 5
		IColo ot	h ol um	OTHER (DISCLOSURE	S (Including A	uthor, Title, Date,	Portinent Dones at	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
	53	Antiboo	dies and (LE EDV-HVNTI	IMAMA TAAA	10010 000 71	Application tiss, Inc. pps.		cer" Monoclonal 160
1	54	Coligan	et al. (Current Prot	ocols in I	mmunology, C	hapter 5, 1(2)	(1991)	
1	55	Cooney Vitro"	et al., Science 2	Site-Specif 41:456-459	ic Oligonu (July 22,	cleotide Bind 1988)	ding Represses	Transcription of	the Human c-myo Gene
*	56	Creigh	on, Thoma	s E. Protei	ns: Struct	ures and Mole	ecular Propert:	ies, N.Y.:W.H. Fr	eeman & Cg. (1983)
-	- 1								
	J								hemistry 13(5):1014-1
	58	Dzau et	al., "Ge	Therapy i	for Cardio	ascular Dise	ase." <u>Trends</u> i	n Biotechnology.	11:205-210 (1993)
+	E	van et	al., "Iso	olation of M	Monoclonal	Antibodies S	nogifi a f		Oncogene Product"
						(====,		* / / /	
	ł						-01141 D2010	₹ 0:\x\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	charomyces cerevisia 988)
1	61 ('ields a 1989)	ind Song.,	"A Novel G	enetic Sys	tem to Detect	Protein-Prot	ein Interactions.	" Nature. 340:245-24
1	F.	ishwild ransgen	et al., ic Mice"	"High-Avidi	ty Human	GK Monoclona	al Antybodies 1 51 (Jul 1996)	From a Novel Stra	in of Minilocus
	G	ruber e	t al., "E	fficient Tu	mor Coll I		1338)		
6	- 1						(1994)		Antibody Expressed in
6	ı				_	Y /			Proc. Natl. Acad. So
6	5 25	olmes et 53 (5025)	al., "Si :1278-128	ructure and	Function	Expression	Of a Human In	terleukin-8 Recep	otor" Science
6	HO 6 V _H	ogenboo Gene S	om and Wir Segments F	nter, "By-Pa Rearranged i	n Nitro	nīsation: Hur . Mol. Biol.	man Antibodies 227:381-388	from Synthetic R	Repertoires of Germli
	Но	pp et a	1., "A Sh	ort Polypep Technology	tide Marko	v Coores	seful for Reco	mbihant Protein I	dentification and
1	- !			\times	1	(ole Microspheres	
 	Jol	hnson e	t al, "A	month-long	effect fro			\	human growth hormone
69	- 1							\	
70	_ / _					•			dy with Those From a
71	1								Natl. Acad. Sci. USA
72	Koh Nat	ler and ure. 25	Milsteir 6:495-497	., "Continu (August 7,	ous Cultur 1975)	es of Fused (Cells Secretin	g Antibody of Pre	defined Specificity.
er er	8	K.	2 . 2 2	whother or			Date (Considered	
		- 196	NVV	wux	1		i	draw line through cit	5/13

FORM PTO-1449

U.S. Dept. of Commerce Patent and Trademark Office

Atty Docket No. P3121R1

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Audrey Goddard et al. Filing Date

26 Sep 2001

		OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Kostelny et al. "Formation of all "Formation o
	73	OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Kostelny et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers" Journal of Immunology 148(5):1547-1553 (1992)
$\overline{}$	- 1	
		Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" The Journal of Immunology 133(6):3001-3005 (1984)
•	75	Lee et al., "Complexes Formed by (Pyrimidine) _n (purine) _n DNAs on Lowering the pH are Three-Stranded." Nucl. Acids Res. 6:3073-3091 (1979)
	76	Lewis "Controlled release of bioactive agents from lactide/glycolide polymers" Biodegradable Polymer as Drug Delivery Systems, M. Chasin and R Langer, New York: Marcel Dekker pps. 1-41 (1990)
	J	Li et al., "Targeted Mutation of the DW Wolf Time Tork Marcel Dekker pps. 1-41 (1990)
7	- 1	Conberg and Huszar., "Human Antibodies From Transgenic Mice" International Reviews of Immunology
7	ĺ	conberg et al., "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic dedifications" Nature 368(6474):856-859 (Apr 28, 1994)
8	ĮS1	Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to tem-loop II of U1 RNA" Proc. Natl. Acad. Sci. USA 87:6898-6317 (1990)
i	1 v:	arasco et al., "Design, intracellular expression, and activity of a human anti-human immunodeficiency irus type 1 gp 120 single-chain antibody" Proc. Nat. Aead. Sci. USA 90:7889-7893 (1993)
	2 <u>B</u> i	io/Technology 10:779-783 (1992)
83		arks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage" J.
84		artin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K+ Chann arrents" <u>Science</u> 255:192-194 (1992)
85	1	errifield, R.B., "Solid Phase Pept de Synthesis. I. The Synthesis of a Tetrapeptide" J. Am. Chem. Soc (14):2149-2154 (Jul 1963)
86	Mi 19	Istein and Cuello, "Hybrid Hybridomas and Their Use in Immunohistochemistry" Nature 305:537-540 (Oct
	Mo	rdenti et al., "The Use of Intergration C
	1	/ 12-13 Pless pps 42-96 (1989)
		rrison, S., "Immunology: Success in Specification" Nature. 368 (6474):812-813 (Apr 28, 1994)
89	Mun	nson and Rodbard, "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding stems" Analytical Biochemistry 107:220-239 (1980)
90	Nex	berger, M., "Generating High-Avidity Human Mabs in Mice" Nature Biotechnology. 14(7):826 (Jul 1996)
/	Nie	lsen et al., "Identification of Probability
		(233)
92	Hete (198	ren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and erobifunctional Cross-Linking Reagents" The Journal of Histochemistry and Cytochemistry 30(5):407-413
miner	6	1 Data Council 1
aminer: Initi	ial if	reference considered whether or not situit is in the first of the firs
not in confo	rmar	nce and not considered. Include copy of this form with next communication to applicant.

. FORM F	" DT∩-14	· · · · · · · · · · · · · · · · · · ·			Sheet 5 of
, FOLUVI I	10-14	MAY 1 2 2003 (2)	U.S. Dept. of Commerce	Atty Docket No.	Sent No.
		· \	Patent and Trademark Office	P3121R1	09/963,994
LIST O	F DISC	LOSURESCITED BY AND LICANT		Applicant	MAL
(Use	Sever	al sheets if necessary)		Audrey Goddard e	ral.
(000	00101	ar sincets if flecessary)		Filing Date	Group 200
		OTHER DISC	CLOSURES (Including Author Title Det	26 Sep 2001	TEASTED OF
	0. 0.2 M	The second of th	CLOSURES (Including Author, Title, Date, cotein Gene and the Function of An	 .	1600/2
	1		36(2):560-56	7 (1991)	_
	Pa 95 it	ain et al., "Preparation of P	rotein A-Peroxidase Monoconjugate " Journal of Immunological Methods	Using a Heterobifu	nctional Reagent, a
	Pl	uckthun., "Antibodies From Fo	echerichia	<u>9</u> 40:219-230 (1981)	
	96 Ex	perimental Pharmacology., Ros	scherichia coli. The Pharmacology senberg and Moore, eds., Berlin:Sp	y of Monoclonal Antoringer-Verlag, Char	ibedies: Handbook o
	Pr	esta, L., "Antibody Engineer:	ing" Curr. Op. Struct. Biol. 2:593	3 - Eng. (1000)	pcci 11, voi.
9	98 Ri	echmann et al., "Reshaping Hu	man Antibodies for Therapy" Natur	e 332/123/327 (Mar	24, 1988)
	Ro	ssi, J.J., "Making Ribozymes	Work in Cells. " Current Biology.		
9				χ	
*10	0 Lak	poratory Press (1989)	ng: A Laboratory Manual, Second e	dition, New York:Co	ld Spring Harbor
10	1199	(2)	Humanized Bispecific Antibodies HER2 Protooncogene" Journal of Exp	perimental Medicine	175.217-225 / Tan 1
1	2 Imm	unology. 148(9):2918-2922 (1	ed Human IgG Mutant With Enhanced	Cytolytic Activity	." Journal of
10:	Ski 3 Dom	nner et al., "Use of the Glu- ain of Normal and Mutant ras	-Glu-Phe C-Terminal Epitope for Ra GTPase-activating Proteins." J. E	apid Purification of	f the Catalytic
	Ste	in and Cohen., "Oligodeoxynuc	cleotides as Inhibitors of Gene Ex	pression: A Review	3-14166 (1991)
104					
105					
*106	Stev	wart et al. Solid-Phase Pepti	de Synthesis, San Francisco, CA:W	.H. Freeman Co. (19	69)
	Sure	esh et al., "Bispegific Monoc	lonal Antibodies from Hybrid Hybr		<u> </u>
107					
108	Thom	as and Capeochi, "Site-Direct. 51:503-512 (Nov 1987)	ted Mutagenesis by Gene Targeting	in Mouse Embryo De:	rived Stem Cells "
				1	
109	Natl	Agad. Sci. USA 77(9):5201-5	natured RNA and Small DNA Fragment 5205 (September 1980)	s Transferred to N	itrocellulose" Proc
- 	Tray		nglo dhair i i	arget Cytotoxic Lym	mphocytes on HIV
	Tutt	et al., "Trispecific F(ab/)	Dom's and a second		
_/			o. Innitation	<u>-</u> 14/(1):60-69 (199	1)
112	Biote	echniques. 6(10):958-976 (198	of Eukaryotic Gene Expression by	Complementary RNA o	r DNA Sequences."
miner		/			
يخ	3 ¹ .	Deminica		Considered 6/30/03	
		eference considered, whether or not e and not considered. Include conv		<i> </i>	

. FUNI	しんしょうしょう	1440			Sheet 6
	WPIO	MAY 1 2 2003	U.S. Dept. of Commerce	Atty Docket No.	Seria No.
		. \ _5	Patent and Trademark Office	P3121R1	09/964,094
LIST	T OF D	ISCLOSURES CITED BY APPLICANT		Applicant	Ma.
(U	Use se	veral sheets if necessary)		Audrey Goddard et Filing Date	The May
				26 Sep 2001	16961/2
		OTHER DISCLOS	URES (Including Author, Title, Date,	Doubles and D	EN 10
\	113	Restrapting Human	Antibodies: Grafting an Anti-	ysozyme Activity"	Science 239.1524
	114	von Heijne, G., "A New Method for 14(11):4683-4690 (1986)	Predicting Signal Sequence Cle	avage Sites" Nucl.	Acids Res.
	115	Wagner et al., "Transferrin-Polyca Acad. Sci. 87:3410-3414 (May 1990)	tion Conjugates as Carriers fo	r DNA Uptake Into (Cells." Proc. Na
		Wells et al., "Cassette Mutagenesi Sites" Gene. 34(2-3):315-323 (1985)	S: An Efficient Mothed for G		Mary Commercial
	7.7.0	Wells, J. et al., "Importance of W Subtilisin" Philos. Trans. Royal So	drogen-Bond Formation in State		
				(A 386)	
	118	Wolff et al., "Monoclonal antibody 53(11):2560-2565 (1993)	homodimers: enhanced antitumos	r activity in nude	mice!! Cancer De
	119	Wu, G.Y. and C. H. Wu., "Receptor-M System." J. Bio. Chem. 262(10):4409	edicted in vitro Gene Transfor	mation by a Soluble	e DNA Carrier
-		Zamecnik et al "Inhibition"			
	120	Zamecnik et al., "Inhibition of Rep in Cultured Cells by Exogenous Synt Sci. 83:4143-4146 (1986)	leation and Expression of Hum hetic Oligonucleotides Complem	ent T-Cell Lymphotro	opic Virus Type
		Zapata et al Engineering		CO VITAL KNA	1 " D1CCA NT_L 1
1	121	Enhanced Antiproliferative Activity	2 ragments for Efficien	t Production in Page	horiahia!
		I DESCRIPTION	Protein Engineering. 8(10):1	057-1062 (1995)	merichia com a
				03/-1062 (1995)	
	122	Zola Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198	Soluble Antigens" Monoclonal	Antibodies: A Manua	1 of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122		Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens Monoclonal 7)	Antibodies: A Manua	l of Techniques
	122	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (1987 Zoller and Smith., "Oligonucleotide-General Procedure for the Production 10(20):6487-6500 (1982)	Soluble Antigens" Monoclonal Directed Mutagenesis Using MI of Point Mutations in Any Fra The state of the	Antibodies: A Manua 3-Derived Vectors: agment of DNA" Nucl	l of Techniques
iner	122 I	Zola "Using Monoclonal Antibodies: Press, Chapter 6, pps. 147-158 (198'	Soluble Antigens" Monoclonal Directed Mutagenesis Using Min of Point Mutations in Any Fra Date Co	Antibodies: A Manua 3-Derived Vectors: agment of DNA" Nucl Onsidered	An Efficient and Acids Res.